Although research into the role of ErbB receptor signalling in breast cancer has focused primarily on EGFR and ErbB2, it is becoming increasingly clear that both ErbB3 and ErbB4 also have important roles to play in this disease. Here, ERBB4 is linked to breast carcinoma.